SO
OCUL icon

STRS Ohio’s Ocular Therapeutix OCUL Stock Holding History

STRS Ohio’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-44,200
Closed -$374K – 2274
2026
Q1 		$374K Hold
44,200
– – ﹤0.01% 1233
2025
Q4 		$537K Buy
+44,200
New +$537K ﹤0.01% 1038
2024
Q1 		– Sell
-38,200
Closed -$170K – 2000
2023
Q4 		$170K Hold
38,200
– – ﹤0.01% 1607
2023
Q3 		$119K Hold
38,200
– – ﹤0.01% 1677
2023
Q2 		$197K Sell
38,200
-19,700
-34% -$117K ﹤0.01% 1591
2023
Q1 		$305K Buy
57,900
+42,000
+264% +$199K ﹤0.01% 1503
2022
Q4 		$44K Hold
15,900
– – ﹤0.01% 1818
2022
Q3 		$65K Buy
+15,900
New +$80.1K ﹤0.01% 1808
2014
Q4 		– Sell
-2,000
Closed -$30K – 1785
2014
Q3 		$30K Buy
+2,000
New +$29.6K ﹤0.01% 1708

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

STRS Ohio's OCUL Position: Q2 2026 in Review

STRS Ohio sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 44,200 shares — an estimated $374K sold.

STRS Ohio first reported a position in OCUL in Q3 2014 and held it in 9 quarters. The position peaked at $537K in Q4 2025. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • STRS Ohio reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
  • STRS Ohio sold 44,200 Ocular Therapeutix shares in Q2 2026, an estimated $374K.
  • STRS Ohio first reported a position in Ocular Therapeutix in Q3 2014 and held it in 9 quarters.
  • STRS Ohio's Ocular Therapeutix position peaked at $537K in Q4 2025.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.